Vasculitis encompasses a group of autoimmune disorders characterized by inflammation of blood vessels, which can lead to significant organ damage and morbidity if left untreated. Although current treatment options for vasculitis aim to suppress inflammation and control disease activity, there is a need for novel therapeutic strategies that can further improve outcomes and minimize side effects. In this article, we will explore recent advancements and emerging approaches in the management of vasculitis, focusing on novel therapeutic strategies that hold promise for the future. Understanding the underlying immunopathogenesis of vasculitis has provided insights into potential therapeutic targets. Recent research has identified specific molecules and pathways involved in the pathogenesis of vasculitis, such as cytokines, chemokines, and cellular adhesion molecules. Advancements in precision medicine have opened new avenues for tailoring therapies to individual patients based on their specific characteristics and disease profiles. Recent research has focused on identifying biomarkers, including genetic variants and molecular signatures, that can predict treatment response and guide personalized therapy in vasculitis. By stratifying patients based on their molecular profiles, clinicians can optimize treatment strategies and minimize adverse effects.
HTML PDFShare this article
Journal of Vasculitis received 83 citations as per Google Scholar report